No difference between the drug and placebo in change in ADAS cognitive subscale score at week 80
FRIDAY, Jan. 26, 2018 (HealthDay News) — For patients with mild Alzheimer’s disease, solanezumab administered every four weeks does not alter cognitive decline, according to a study published in the Jan. 25 issue of the New England Journal of Medicine.
Lawrence S. Honig, M.D., Ph.D., from Columbia University Medical Center in New York City, and colleagues conducted a double-blind, placebo-controlled trial involving patients with mild dementia due to Alzheimer’s disease. A total of 2,129 patients were enrolled and randomized to receive solanezumab (400 mg; 1,057 patients) or placebo (1,072 patients) intravenously every four weeks for 76 weeks.
The researchers found that the mean change from baseline in the score on the 14-item cognitive subscale of the Alzheimer’s Disease Assessment Scale score was 6.65 and 7.44 in the solanezumab and placebo groups, respectively, with no significant difference between the groups at week 80 (difference, −0.8; 95 percent confidence interval, −1.73 to 0.14; P = 0.1). The change from baseline in the Mini-Mental State Examination score was −3.17 and −3.66 in the solanezumab and placebo groups, respectively.
“Solanezumab at a dose of 400 mg administered every four weeks in patients with mild Alzheimer’s disease did not significantly affect cognitive decline,” the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which funded the study.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Copyright © 2018 HealthDay. All rights reserved.
